Ponatinib (Iclusig; Takeda) combined with reduced-intensity chemotherapy achieved higher minimal residual disease-negative complete remission rates in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia compared to imatinib.
Investigators find that despite the same quantity of respiratory syncytial virus and presentation, some of the samples demonstrated signs of greater damage to cells.
Complete due diligence before selecting a compounding pharmacy and establishing an outsourcing relationship.
Despite an apparent benefit of intravenous immunoglobulin (IVIG) on early discharge, the likelihood of needing second-line treatment was 3 times higher in patients who initiated treatment with IVIG alone.
Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products.
Analysis of central Missouri discovers differences in co-infection occurrence between Delta and Omicron variants.
Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.
cobas MPXV targets 2 different regions of the monkeypox virus genome that are less prone to mutations than other parts of the genome.
In a 2019 survey, middle-aged participants were considerably more apprehensive about getting vaccinated than younger groups, which was not the case in the 2022 survey.
Technology gains traction in health-system pharmacies for drug inventory and to automate applications.
Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Approximately 80% of all HIV infections among teens are from the gay and bisexual population.
Study suggests states maintaining higher health care expenditures are more attentive to price transparency initiatives and tend to adopt all-payer claims databases.
NVX-CoV2373 is a protein-based vaccine developed from the genetic sequence of the first strain of SARS-CoV-2.
Dapagliflozin and standard of care found to slow the decline in kidney function and lower the incidence of kidney failure.
New COVID-19 variants are always cause for concern but are not a cause for panic.
PrEP reduces the risk of getting HIV from sex by about 99% for certain patient population with consistent adherence.
Zilucoplan is a subcutaneous, self-administered peptide inhibitor of complement component 5.
GDA-501, a novel, genetically modified, nicotinamide natural killer pre-clinical cell therapy.
Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.
Despite evidence of a higher risk of myocarditis or pericarditis with COVID-19 vaccination, immunization should still be recommended because the benefits likely outweigh the harms, study shows.
Direct-acting antivirals have high efficacy for hepatitis C, however, patients with advanced liver scarring are at risk for the development of secondary diseases.
New continuous glucose monitor systems provide additional support and quality of life improvements for patients with diabetes.
States with a higher prevalence of Medicaid patients with type 2 diabetes were found to have lower use ratio of glucose-lowering agents with known cardiovascular benefits.
Under specific circumstances and criteria, they are adjustable to approximate OS in selected populations of Canadian patients who have advanced non–small cell lung cancer.
Analysis indicates that a 25-mg dose reduces the condition scores significantly more than a 1mg dose over a 3-week period, but the 10-mg dose did not yield the same results.
Tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy approved for the treatment of adults with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.
Intravenous immunoglobulin is used for several autoimmune and inflammatory conditions, although researchers have not fully understood its specific mechanisms.
FDA approves brentuximab vedotin for the treatment of patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
The most common cause of death for patients with non-alcoholic fatty liver disease is cardiovascular disease, but it also increases the risk of hepatocellular carcinoma and may surpass hepatitis B and C as the leading cause of this cancer.
